An overview on gene therapy programs

Drug News and Perspectives

Volumn 21, Issue 6, 2008, Pages 345-351

  Romano, Gaetano ^a  

^a Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CG 0070; CHIMERICAL ANTIGEN RECETOR; CRS 207; DEOXYRIBONUCLEOPROTEIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; LIPOSOME; LYMPHOCYTE ANTIGEN RECEPTOR; MESOTHELIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; ONCOVEX; PARVOVIRUS VECTOR; PLACEBO; PLASMID DNA; PROTEIN LMO2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER CANCER; BLADDER DISCOMFORT; CANCER GENE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ELECTROPORATION; FATIGUE; FEVER; GENE INSERTION; GENE MUTATION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC IMMUNIZATION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HEMATURIA; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; RETROPOSON; RIGOR; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 56249147513     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.6.1260760     Document Type: Conference Paper

References (63)

1. Romano, G. Gene transfer in experimental medicine. Drug News Perspect 2003, 16(5): 267-76.
2. Romano, G. Current development of lentiviral-mediated gene transfer. Drugs News Perspect 2005, 18(2): 128-34.
3. Romano, G. The controversial role of adenoviral-mediated gene transfer in gene therapy programs: where do we stand? Drugs News Perspect 2006, 19(2): 99-106.
4. Marshall, E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science 2002, 298(5591): 34-5.
5. Buckley, R.H. Gene therapy for SCID - A complication after remarkable progress. Lancet 2002, 360(9341): 1185-6.
6. Check, E. Second cancer halts gene therapy clinical trials. Nature 2003, 421(692): 305.
7. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644): 415-9.
8. McCormack, M.P. and Rabbitts, T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350(9): 913-22.
9. Pike-Overzet, K., van der Burg, M., Wagemaker, G. et al. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007, 15(11): 1910-6.
10. Baum, C. What are the consequences of the fourth case? Mol Ther 2007, 15(8): 1401-2.
11. Edelstein, M.L., Abedi, M.R. and Wixon, J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007, 9(10): 833-42.
12. Institute of Child Health, Great Ormond Street Hospital NHS Trust, London, UK Severe adverse event in clinical trial of gene therapy for X-SCID. http://www.asgt.org/UserFiles/XSCIDstatement.pdf. Accessed July 3, 2008.
13. Nemunaitis, J.J., McKierman, J.M., Lamm, D.L. et al. Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer(NMBC). Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 687.
14. GM-CSF an immune-enhanced oncolytic herpes simplex type-1 virus, in unresectable metastatic melanoma. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 301.
15. Nemunaitis, J.J., Senzer, N., Bedell, C. et al. A phase 1 clinical trial of CRS-207 in advanced solid tumor patients. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 168.
16. Brentjens, R.J., Hollyman, D.R., Weiss, M. et al. A phase I trial for the treatment of chemo-refractory chronic lymphocytic leukemia with CD19-targeted autologous T cells. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 38.
17. Howe, S.J., Mansour, M., Brugman, M.H. et al. Molecular analysis of a severe event in the UK SCID-X1 gene therapy clinical trial. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 297.
18. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466): 669-72.
19. Giordano, A., Fucito, A., Romano, G. and Marino, I.R. Carcinogenesis and environment: the cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front Biosci 2007, 12: 3475-82.
20. Gan, D.D., Macaluso, M., Cinti, C. et al. How does a normal cell become a cancer cell? J Exp Clin Cancer Res 2003, 22(4): 509-16.
21. Romano, G. The role of adult stem cells in carcinogenesis. Drug News Perspect 2005, 18(9): 555-9.
22. Romano, G., Claudio, P.P., Tonini, T. and Giordano, A. Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur J Dermatol 2003, 13(5): 424-9.
23. Sallberg M., Frelin, L., Ahlen, G. et al. A phase I/II clinical trial of therapeutic vaccination with a DNA plasmid expressing the hepatitis C virus (HCV) non-structural 3/4A complex delivered by in vivo electroporation to patients with chronic HCV infection. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 29-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 715.
24. Lavanchy, D. Worlwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005, 34(Suppl. 1): S1-3.
25. Cougot, D., Neuveut, C. and Buendia, M.A. HBV-induced carcinogenesis. J Clin Virol 2005, 34(Suppl. 1): S75-8.
26. Villeneuve, J.P. The natural history of chronic hepatitis B infection. J Clin Virol 2005, 34(Suppl. 1): S139-42.
27. Levrero, M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25(27): 3834-47.
28. Alisi, A., Giambartolomei, S., Cupelli, F. et al. Physical and functional interaction between HCV core protein and different p73 isoforms. Oncogene 2003, 22(17): 2573-80.
29. Cho, J., Baek, W., Yang, S. et al. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochim Biophys Acta 2001, 1538(1): 59-66.
30. Lu, W. and Ou, J.H. Phosphorylation of hepatitis C core protein by protein kinase A and protein kinase C. Virology 2002, 300(1): 20-30.
31. Ray, R.B., Steele, R., Meyer, K. and Ray, R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997, 272(17): 10983-6.
32. Ishido, S., Muramatsu, S., Fujita, T. et al. Wild-type, but not mutant type, p53 enhances nuclear accumulation of the NS3 protein of hepatitis C virus. Biochem Biophys Res Commun 1997, 230(2): 431-6.
33. Ishido, S. and Hotta, H. Complex formulation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 1998, 438(3): 258-62.
34. Sakamuro, D., Furukawa, T. and Takegami, T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995, 69(6): 3893-6.
35. Tu, H., Gao, L., Shi, S.T. et al. Hepatitis C virus RAA polymerase and NS5A complex with a SNARE-like protein. Virology 1999, 263(1): 30-41.
36. Chung, K.M., Lee, J., Kim, J.E. et al. Nonstructural protein 5A of hepatitis C virus inhibits the function of karyopherin beta3. J Virol 2000, 74(11): 5233-41.
37. Gale, M.J., Korth, M.J., Tang, N.M. et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997, 230(2): 217-27.
38. Polyak, S.J., Khabar, K.S., Paschal, D.M. et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001, 75(13): 6095-106.
39. Kittlesen, D.J., Chianese-Bullock, K.A., Yao, Z.Q. et al. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000, 106(10): 1239-49.
40. Foy, E., Li, K., Wang, C. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300(5622): 1145-8.
41. Romano, G. The standpoint of gene therapy programs. Drug News Perspect 2007, 20(5): 335-43.
42. Romano, G. Current development of nonviral-mediated gene transfer. Drug News Perspect 2007, 20(4): 227-31.
43. Dalsgaard, T., Moldt, B., Sharma, N. et al. Silencing and insulation of Sleeping Beauty-based vectors in early embryonal cells. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 330.
44. Vanden Driessche, T., Belay, E., Matrai, J. et al. Novel enhanced transposases result in robust stable gene transfer into hematopoietic, mesenchymal and muscle stem/progenitor cells ex vivo and hepatocyles in vivo. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 331.
45. Olson, E.R., Hyland, K.A., Bostrom, K. et al. Non-immunogenic, secretable canine reporters for long-term gene expression studies in the dog using the Sleeping Beauty transposon system. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 332.
46. Chen, Y., Kren, B.T., Steer, C.J. Sleeping Beauty expression in BOEC is significantly increased with the b-globin MAR element. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 486.
47. Liesner, R., Nachtigail, I., Ehrhardt, A. A mutational analysis of the phiC31 integrase DNA binding domain identifies critical amino acids defining activity and binding to attachment sites. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 482.
48. Chavez, C.L., Hoyt, J.J., Calos, M.P. Directed evolution of phage phiC31 integrase towards a single locus on human chromosome Xq22.1. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 328.
49. Sharma, N., Moldt, B., Dalsgaard, T. et al. Regulated gene insertion by steroid-induced phiC31 integrase. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 329.
50. Philpott, N.J. and Thrasher, A.J. Use of non-integrating lentiviral vectors for gene therapy. Hum Gene Ther 2007, 18(6): 483-9.
51. Philippe, S., Sarkis, C., Barkats, M. et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A 2006, 103(47): 17684-9.
52. Vargas, J., Gusella, G,L,, Najfeld, V. et al. Novel integrase-defective lentiviral episomal vectors for gene therapy. Hum Gene Ther 2004, 15(4): 361-72.
53. Tarskikh, A.V., Ershler, M.A., Drize, N.J. et al. Long-term persistence of a nonintegrated letniviral vector in mouse hematopoietic stem cells. Exp Hematol 2005, 33(8): 873-82.
54. Apolonia, L., Waddington, S.N., Fernandes, C. et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007, 15(11): 1947-54.
55. Nightingale, S.J., Hollis, R.P., Pepper, K.A. et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006, 13(6): 1121-32.
56. Yanez-Munoz, R.J., Balaggan, K.S., MacNeil, A. et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12(3): 348-53.
57. Kawai, T., Choi, U., Changpriroa, C. et al. Human hematopoietic stem cells infected with integration defective lentivirus vector encoding C-terminus trancated hyperfunctional CXCR4 demonstrate enhanced engraftment in NOD/SCID mice. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 305.
58. Bayer, M.A., Ma, H., Yanez-Munoz, R.J., Kafri, T. A second look al lentiviral episome formation. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 311.
59. Baiker, A., Maarcker, C., Piechaczek, C. et al. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000, 2(3): 182-4.
60. Lufino, M.M., Manservigi, R. and Wade-Martins, R. An S/MAR-based infectious episomal DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. Nucleic Acids Res 2007, 35(15): e98.
61. Papapetrou, E.P., Ziros, P.G., Micheva, I.D. et al. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther 2006, 13(1): 40-51.
62. Argyros, O., Wong, S.P., Niceta, M. et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 493.
63. Haase, R., Ogris, M., Lipps, H.J., Baiker, A. Optimization of the non-viral, episomally replicating vector pEPI-1 for efficient gene delivery. Mol Ther [11th Annu Meet Am Soc Gene Ther (ASGT) (May 28-June 1, Boston) 2008] 2008, 16(Suppl. 1s): Abst 487.